Track PE‑22‑28 in Peptimes™
PE-22-28 is a 7-amino-acid peptide designed from spadin, a peptide that NLM's MeSH describes as derived from the propeptide of sortilin and as a TREK-1 antagonist (a blocker of the TREK-1 channel). (Source: NLM MeSH.)
Is PE-22-28 FDA-approved?
No. PE-22-28 isn't FDA-approved, and Drugs@FDA lists no application with it as an active ingredient.
PE-22-28
Also: PE 22-28
- Status label in the Peptimes Library
- Not FDA-Approved
- Routes in Peptimes
- SubcutaneousIntramuscularOralSublingualNasalTopicalOther
- Updated
- 1 Nov 2026
US regulatory status
What studies have looked at
Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.
- In animals or the lab
In cells, PE 22-28 blocked the TREK-1 channel more strongly than spadin. In mice it reduced immobility in the forced-swim test and increased new nerve-cell formation in the hippocampus. Mouse and cell data only.
Source: PMID 28955242, checked 1 Nov 2026
How to track it in Peptimes
Add PE-22-28 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Not FDA-Approved”.
- Routes: the app lets you record whichever route you used; none is established. Its routes are subcutaneous, intramuscular, oral, sublingual, nasal, topical and Other.
- Logging: the amount you took, the route and how you feel.
- Injection sites: subcutaneous and intramuscular doses record the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next. Other routes skip this step.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell PE-22-28 or any other compound.
More sources
- Djillani et al., 2017, PMID 28955242, checked 1 Nov 2026: PE 22-28 is a 7-amino-acid peptide the authors designed from spadin’s breakdown products.
- NLM, MeSH, spadin peptide, checked 1 Nov 2026: derived from the propeptide of sortilin; a TREK-1 antagonist.
- ClinicalTrials.gov, searched 1 Nov 2026: no registered study of PE 22-28 or spadin.